Inhibition of fibroblast growth factor receptor 3 induces differentiation and apoptosis in t(4;14) myeloma.

We have previously shown that dysregulation of fibroblast growth factor receptor 3 (FGFR3) by the t(4;14) translocation is a primary event in multiple myeloma (MM) and that activating mutations of FGFR3 are acquired in some cases. We describe here inhibition of wild-type (WT) and constitutively activated mutant FGFR3 autophosphorylation by the small molecule inhibitor, PD173074. Inhibition of FGFR3 in human myeloma cell lines was associated with decreased viability and tumor cell growth arrest. Further, morphologic, phenotypic, and functional changes typical of plasma cell (PC) differentiation, including increase in light-chain secretion and expression of CD31, were observed and this was followed by apoptosis. Finally, using a mouse model of FGFR3 myeloma, we demonstrate a delay in tumor progression and prolonged survival of mice treated with PD173074. These results indicate that inhibition of FGFR3, even in advanced disease associated with multiple genetic changes, may allow the cell to complete its developmental program and render it sensitive to apoptotic signals. In addition, this represents the validation of a therapeutic target in MM that may benefit patients who have a very poor prognosis with currently available treatments.

[1]  P. Richardson,et al.  Novel therapeutic approaches for multiple myeloma , 2003, Immunological reviews.

[2]  M. Rue,et al.  Clinical and biologic implications of recurrent genomic aberrations in myeloma. , 2003, Blood.

[3]  G. Mills,et al.  Loss of PTEN/MMAC1/TEP in EGF receptor-expressing tumor cells counteracts the antitumor action of EGFR tyrosine kinase inhibitors , 2003, Oncogene.

[4]  F. Zhan,et al.  CD27 is heterogeneously expressed in multiple myeloma: low CD27 expression in patients with high‐risk disease , 2003, British journal of haematology.

[5]  F. Zhan,et al.  A subset of multiple myeloma harboring the t(4;14)(p16;q32) translocation lacks FGFR3 expression but maintains an IGH/MMSET fusion transcript. , 2003, Blood.

[6]  K. Anderson,et al.  The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications. , 2003, Blood.

[7]  Tony Reiman,et al.  In multiple myeloma, t(4;14)(p16;q32) is an adverse prognostic factor irrespective of FGFR3 expression. , 2003, Blood.

[8]  S. Rudikoff,et al.  An unusual H-Ras mutant isolated from a human multiple myeloma line leads to transformation and factor-independent cell growth , 2003, Oncogene.

[9]  B. Barlogie,et al.  Antimyeloma efficacy of thalidomide in the SCID-hu model. , 2002, Blood.

[10]  R. Bataille,et al.  Recurrent 14q32 translocations determine the prognosis of multiple myeloma, especially in patients receiving intensive chemotherapy. , 2002, Blood.

[11]  D. Neuberg,et al.  Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model. , 2002, Cancer research.

[12]  A. D. Van den Abbeele,et al.  Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. , 2002, The New England journal of medicine.

[13]  Kenneth Chu,et al.  Sustained Loss of a Neoplastic Phenotype by Brief Inactivation of MYC , 2002, Science.

[14]  P. L. Bergsagel,et al.  The enigma of ectopic expression of FGFR3 in multiple myeloma: a critical initiating event or just a target for mutational activation during tumor progression. , 2002, Current opinion in hematology.

[15]  B. Smith,et al.  A FLT3-targeted tyrosine kinase inhibitor is cytotoxic to leukemia cells in vitro and in vivo. , 2002, Blood.

[16]  Donna Neuberg,et al.  CT53518, a novel selective FLT3 antagonist for the treatment of acute myelogenous leukemia (AML). , 2002, Cancer cell.

[17]  Doriano Fabbro,et al.  Inhibition of mutant FLT3 receptors in leukemia cells by the small molecule tyrosine kinase inhibitor PKC412. , 2002, Cancer cell.

[18]  R. Noelle,et al.  Short-lived and Long-lived Bone Marrow Plasma Cells Are Derived from a Novel Precursor Population , 2002, The Journal of experimental medicine.

[19]  John Crowley,et al.  Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cells. , 2002, Blood.

[20]  J. Melo,et al.  The t(8;22) in chronic myeloid leukemia fuses BCR to FGFR1: transforming activity and specific inhibition of FGFR1 fusion proteins. , 2001, Blood.

[21]  L. Baldini,et al.  Analysis of FGFR3 gene mutations in multiple myeloma patients with t(4;14) , 2001, British journal of haematology.

[22]  A. Neri,et al.  Deregulated FGFR3 mutants in multiple myeloma cell lines with t(4;14): comparative analysis of Y373C, K650E and the novel G384D mutations , 2001, Oncogene.

[23]  P. L. Bergsagel,et al.  The myeloma-associated oncogene fibroblast growth factor receptor 3 is transforming in hematopoietic cells. , 2001, Blood.

[24]  C. Sawyers,et al.  Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. , 2001, The New England journal of medicine.

[25]  W. Kuehl,et al.  Activated fibroblast growth factor receptor 3 is an oncogene that contributes to tumor progression in multiple myeloma. , 2001, Blood.

[26]  E. Cesarman,et al.  Telomerase activity in B‐cell non‐Hodgkin lymphoma , 2000, Cancer.

[27]  P. L. Bergsagel,et al.  Ectopic expression of fibroblast growth factor receptor 3 promotes myeloma cell proliferation and prevents apoptosis. , 2000, Blood.

[28]  D. Chopin,et al.  Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas , 1999, Nature Genetics.

[29]  E. Buchdunger,et al.  In vivo eradication of human BCR/ABL-positive leukemia cells with an ABL kinase inhibitor. , 1999, Journal of the National Cancer Institute.

[30]  S. Hubbard,et al.  Crystal structure of an angiogenesis inhibitor bound to the FGF receptor tyrosine kinase domain , 1998, The EMBO journal.

[31]  Andreas Radbruch,et al.  Lifetime of plasma cells in the bone marrow , 1997, Nature.

[32]  E. Schröck,et al.  Frequent translocation t(4;14)(p16.3;q32.3) in multiple myeloma is associated with increased expression and activating mutations of fibroblast growth factor receptor 3 , 1997, Nature Genetics.

[33]  B. Klein,et al.  Interleukin-6 in human multiple myeloma. , 1995, Blood.

[34]  W. Giaretti.  A model of DNA aneuploidization and evolution in colorectal cancer. , 1994, Laboratory investigation; a journal of technical methods and pathology.

[35]  C. Chastang,et al.  Tretinoin with chemotherapy in newly diagnosed acute promyelocytic leukaemia , 1994, The Lancet.

[36]  E. Dmitrovsky,et al.  Differentiation therapy of acute promyelocytic leukemia with tretinoin (all-trans-retinoic acid). , 1991, The New England journal of medicine.

[37]  T G Cotter,et al.  HL‐60 cells induced to differentiate towards neutrophils subsequently die via apoptosis , 1990, Clinical and experimental immunology.

[38]  T. Hideshima,et al.  Immunomodulatory analogs of thalidomide inhibit growth of Hs Sultan cells and angiogenesis in vivo , 2003, Leukemia.

[39]  K. Pulford,et al.  Model of inhibition of the NPM-ALK kinase activity by herbimycin A. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[40]  D. Fabbro,et al.  Inhibition of mutant FLT 3 receptors in leukemia cells by the small molecule tyrosine kinase inhibitor PKC 412 , 2002 .

[41]  R. Hardy,et al.  B cell development pathways. , 2001, Annual review of immunology.

[42]  B. Barlogie,et al.  Primary myeloma cells growing in SCID-hu mice: a model for studying the biology and treatment of myeloma and its manifestations. , 1998, Blood.

[43]  P. L. Bergsagel,et al.  The t(4;14) translocation in myeloma dysregulates both FGFR3 and a novel gene, MMSET, resulting in IgH/MMSET hybrid transcripts. , 1998, Blood.

[44]  D N Shapiro,et al.  Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma. , 1994, Science.